Nkarta Q1 2022 Earnings Report
Key Takeaways
Nkarta reported positive preliminary data for NKX101 and NKX019, validating their allogeneic NK cell platform. They have over $400 million in cash and short-term investments following a $230 million public offering in April 2022.
Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen achieved complete response with full hematologic recovery.
Positive preliminary data reported from NKX019 Phase 1 study in patients with relapsed / refractory NHL; 5 of 6 patients treated with a 3-dose regimen achieved response and 3 of 6 achieved complete response.
NKX101 and NKX019 have an encouraging safety profile, without the burdensome mix of side effects associated with CAR T cell approaches.
Nkarta has more than $400 million in cash and short-term investments following April 2022 $230 million public offering of common stock.
Nkarta
Nkarta
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025. This guidance reflects the proceeds received following the April 2022 public offering of common stock.